Colorectal Cancer
RSSArticles
-
Pharmacology Watch
Rivaroxaban may be dabigatran's first competitor; a new way to measure non-adherence to medication therapy; FDA Actions. -
Finding Optimal Therapy for Gastric Cancer
A trial undertaken by EORTC was designed to determine if neoadjuvant chemotherapy would be successful in the absence of post-surgical chemotherapy in enhancing overall survival in patients with locally advanced gastric cancer. The trial did not accrue sufficient numbers of patients to demonstrate a survival benefit. However, presurgical chemotherapy was associated with a higher rate of complete resection and fewer positive lymph nodes, features that suggest progression-free and overall survival might be favorably affected. -
Treating Colon Cancer in Patients with Diabetes
In a retrospective review of consecutive patients with colon cancer, the presence of diabetes mellitus was found to confer negative prognostic information with regard to overall, and cancer-specific, survival. Notably, it was in patients with stage II disease that the presence of diabetes was of most importance. -
Clinical Briefs in Primary Care Supplement
-
Risk of Lymph Node Metastasis in T1 Colorectal Carcinoma
-
Subsite-Specific Incidence Rate And Stage Of Disease in Colorectal Cancer by Race, Gender, and Age Group in the United States
-
Pharmacology Watch: GlaxoSmithKline Withdraws Lymerix: Company ‘Cuts Losses’ on Controversial Lyme Disease Vaccine
-
Rehab joins with oncology to offer massage
-
Antibody-Mediated Pure Red-Cell Aplasia in Patients Treated with Recombinant Erythropoietin
-
Laparoscopic Colectomy for Cancer Offers Minimal Short-Term Benefit Over Open Colectomy